Company / Accounts Receivable
Kiniksa Pharmaceuticals International, plc Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$15.6M
FY2025
5-year range
$4.0M / $41.7M
FY2021-FY2025
Trend
-62.6%
vs FY2024
Sector context
#92 of 115
Health Care
What the data says
Kiniksa Pharmaceuticals International, plc's accounts receivable of $16M is lower than 80% of companies in the Health Care sector (FY2025). Declined from $21M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2025 with a 3-year CAGR of +7.2%.
Declined from $21M to $16M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 115This company $15.6M Sector average $1.1B
▼
-98.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +7.2%, indicating consistent growth.
- In FY2025, accounts receivable decreased 62.6% year-over-year.
- Ranks #92 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.6M | -62.6% |
| FY2024 | $41.7M | +96.2% |
| FY2023 | $21.3M | +68.0% |
| FY2022 | $12.7M | +217.7% |
| FY2021 | $4.0M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026